Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
ChromaDex Appoints Scripps Research Professor of Molecular Medicine, Brunie H. Felding, PhD, to the Scientific Advisory Board | ||
By: Nasdaq / GlobeNewswire - 23 Jul 2019 | Back to overview list |
|
Renowned Cancer Researcher to Support Ongoing Clinical Studies to Further Demonstrate the Safety and Efficacy of NAD+ LOS ANGELES, July 23, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today it has appointed Brunie H. Felding, Ph.D., Associate Professor, Department of Molecular Medicine, Scripps Research Institute, California Campus, to the Scientific Advisory Board (SAB). ChromaDex CEO Rob Fried stated, “We are intrigued by what we have learned about NAD precursors and breast cancer prevention and treatment from Dr. Felding’s research, and share her vision for future studies and the impact the results could have for so many people battling this horrible disease.” The group of scientists Dr. Felding leads at Scripps has conducted research that has shown that increasing NAD+ with the B3 vitamin nicotinamide prevented breast cancer development in mice. Her research findings in the area of mechanisms and inhibition of tumor metastasis have been published in dozens of journals including Cancer Cell, Journal of Clinical Investigation and the Journal of Neuro-Oncology. “I’m honored to join the ChromaDex Scientific Advisory Board and partner with world-leading scientists to further progress the growing body of science on the safety and full therapeutic treatment and preventative potential of NAD+ supplementation for breast cancer," said Dr. Felding. The goal of Dr. Felding’s research is to understand mechanisms of cancer progression and to develop new regimens for prevention and treatment. Dr. Felding received her Ph.D. in Biochemistry from Philipps University Marburg, Germany in 1984; and Master of Science degree in Biology from Justus-Liebig University of Giessen, Germany in 1980. After post-doctoral studies at the Fred Hutchinson Cancer Research Center (Seattle) and Scripps Research (La Jolla) she led a pharmaceutical research group at Merck (Germany) before returning to Scripps where she was appointed to Associate Professor in 2003. For more information about her research, visit: https://www.scripps.edu/felding/. Dr. Felding’s professional background also includes serving on the Board of Directors of the Metastasis Research Society (2010 – 2014). To date, ChromaDex has invested millions of dollars in safety and human clinical trials on its patent-protected NR (commercially known as Niagen) and has entered research agreements with more than 160 leading institutions for research, including Dartmouth, the National Institutes of Health, University of Iowa, and the Scripps Research Institute. About ChromaDex: Forward-Looking Statements: ChromaDex Media Contact: ChromaDex Investor Relations Contact: |
||
|
||
Copyright 2019 Nasdaq / GlobeNewswire | Back to overview list |